References
-
Steinberg
D
Gotto
AM
Jr Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside JAMA 1999 Dec 1 282 21 2043 50 - Nissen SE Nicholls SJ Sipahi I .; ASTEROID Investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 2006 Apr 5 295 13 1556 65
- Anitschkow N Über die Veränderungen der Kaninchenaorta bei experimenteller Cholesterinsteatose Beitr Pathol Anat 1913 56 379 404
- Keys A Aravanis C Blackburn HW Epidemiological studies related to coronary heart disease: characteristics of men aged 40–59 in seven countries Acta Med Scand Suppl 1966 460 1 392
-
Kannel
WB
Dawber
TR
Kagan
A
Revotskie
N
Stokes
J
3rd Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study Ann Intern Med 1961 Jul 55 33 50 - Gofman JW Lindgren F The role of lipids and lipoproteins in atherosclerosis Science 1950 Feb 17 111 2877 166 71
- Khachadurian AK The Inheritance of Essential Familial Hypercholesterolemia Am J Med 1964 Sep 37 402 7
- Goldstein JL Brown MS Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol Proc Natl Acad Sci U S A 1973 Oct 70 10 2804 8
- Goldstein JL Brown MS The LDL receptor Arterioscler Thromb Vasc Biol 2009 Apr 29 4 431 8
- W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators Lancet 1980 Aug 23 2 8191 379 85
- Clofibrate and niacin in coronary heart disease JAMA 1975 Jan 27 231 4 360 81
- Canner PL Berge KG Wenger NK Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 1986 Dec 8 6 1245 55
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA 1984 Jan 20 251 3 351 64
- Endo A The discovery and development of HMG-CoA reductase inhibitors J Lipid Res 1992 Nov 33 11 1569 82
- Endo A A gift from nature: the birth of the statins Nat Med 2008 Oct 14 10 1050 2
- Endo A A historical perspective on the discovery of statins Proc Jpn Acad Ser B Phys Biol Sci 2010 86 5 484 93
- Tsujita Y Kuroda M Tanzawa K Kitano N Endo A Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase Atherosclerosis 1979 Mar 32 3 307 13
- Kuroda M Tsujita Y Tanzawa K Endo A Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase Lipids 1979 Jun 14 6 585 9
- Yamamoto A Sudo H Endo A Therapeutic effects of ML-236B in primary hypercholesterolemia Atherosclerosis 1980 Mar 35 3 259 66
- Alberts AW Chen J Kuron G Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent Proc Natl Acad Sci U S A 1980 Jul 77 7 3957 61
- Furberg CD Pitt B Withdrawal of cerivastatin from the world market Curr Control Trials Cardiovasc Med 2001 2 5 205 7
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994 Nov 19 344 8934 1383 9
- Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 1998 Nov 5 339 19 1349 57
- Sacks FM Pfeffer MA Moye LA The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 1996 Oct 3 335 14 1001 9
- Shepherd J Cobbe SM Ford I Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 1995 Nov 16 333 20 1301 7
- Shepherd J Blauw GJ Murphy MB .; PROSPER study group PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 2002 Nov 23 360 9346 1623 30
- Downs JR Clearfield M Weis S Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 1998 May 27 279 20 1615 22
- Colhoun HM Betteridge DJ Durrington PN .; CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004 Aug 21 27 364 9435 685 96
- Sever PS Dahlöf B Poulter NR .; ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 2003 Apr 5 361 9364 1149 58
- Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002 Jul 6 360 9326 7 22
- Cannon CP Braunwald E McCabe CH .; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 2004 Apr 8 350 15 1495 504
- LaRosa JC Grundy SM Waters DD Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 2005 Apr 7 352 14 1425 35
- Ridker PM Danielson E Fonseca FA .; JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 2008 Nov 20 359 21 2195 207
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 1993 Jun 16 269 23 3015 23
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001 May 16 285 19 2486 97
- Grundy SM Cleeman JI Merz CN .; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004 Jul 13 110 2 227 39
- Stone NJ Robinson JG Lichtenstein AH 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2014 Jun 24 129 25 Suppl 2 S1 45
- Zhang H Plutzky J Skentzos S Discontinuation of statins in routine care settings: a cohort study Ann Intern Med 2013 Apr 2 158 7 526 34
- Lin I Sung J Sanchez RJ Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk J Manag Care Spec Pharm 2016 Jun 22 6 685 98
- Daskalopoulou SS Delaney JA Filion KB Brophy JM Mayo NE Suissa S Discontinuation of statin therapy following an acute myocardial infarction: a population-based study Eur Heart J 2008 Sep 29 17 2083 91
- Nielsen SF Nordestgaard BG Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study Eur Heart J 2016 Mar 14 37 11 908 16
- Banach M Rizzo M Toth PP Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel Expert Opin Drug Saf 2015 Jun 14 6 935 55
- Toth PP Patti AM Giglio RV Management of Statin Intolerance in 2018: Still More Questions Than Answers Am J Cardiovasc Drugs 2018 Jun 18 3 157 73
- Bruckert E Hayem G Dejager S Yau C Bégaud B Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study Cardiovasc Drugs Ther 2005 Dec 19 6 403 14
- U.S. Food and Drug Administration [Internet] Silver Spring, MD U.S. Food and Drug Administration c2018 FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs; 2016 Jan 19 [cited 2018 Oct 2]. Available from https://www.fda.gov/Drugs/DrugSafety/ucm293101.htm
- Power TP Ke X Zhao Z Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease Vasc Health Risk Manag 2018 Feb 5 14 23 36
- Ference BA Yoo W Alesh I Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 2012 Dec 25 60 25 2631 9
- Cannon CP Blazing MA Giugliano RP Ezetimibe Added to Stat in Therapy after Acute Coronary Syndromes N Engl J Med 2015 Jun 18 372 25 2387 97
- Sabatine MS Giugliano RP Keech AC .; FOURIER Steering Committee and Investigators Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease N Engl J Med 2017 May 4 376 18 1713 22
- Gauthier JM Massicotte A Statins and their effect on cognition: Let's clear up the confusion Can Pharm J (Ott) 2015 May 148 3 150 5
- Rojas-Fernandez CH Goldstein LB Levey AI Taylor BA Bittner V The National Lipid Association's Safety Task Force An assessment by the Statin Cognitive Safety Task Force: 2014 update J Clin Lipidol 2014 May–Jun 8 3 Suppl S5 16
- Collins R Armitage J Parish S Sleight P Peto R Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 2004 Mar 6 363 9411 757 67
- Trompet S van Vliet P de Craen AJ Pravastatin and cognitive function in the elderly. Results of the PROSPER study J Neurol 2010 Jan 257 1 85 90
- Giugliano RP Mach F Zavitz K Cognitive Function in a Randomized Trial of Evolocumab N Engl J Med 2017 Aug 17 377 7 633 43
- Schwartz GG Steg PG Szarek M .; ODYSSEY OUTCOMES Committees and Investigators Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome N Engl J Med 2018 Nov 29 379 22 2097 2107
- Ridker PM Pradhan A MacFadyen JG Libby P Glynn RJ Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 2012 Aug 11 380 9841 565 71
- Preiss D Seshasai SR Welsh P Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 2011 Jun 22 305 24 2556 64
- Waters DD Ho JE DeMicco DA Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 2011 Apr 5 57 14 1535 45
- Ridker PM Everett BM Thuren T .; CANTOS Trial Group Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease N Engl J Med 2017 Sep 21 377 12 1119 31
- Bohula EA Giugliano RP Cannon CP Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT Circulation 2015 Sep 29 132 13 1224 33
- Ridker PM Danielson E Fonseca FA Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 2009 Apr 4 373 9670 1175 82
DOI: https://doi.org/10.14797/mdcj-15-1-23 | Journal eISSN: 1947-6108
Language: English
Page range: 23 - 31
Published on: Jan 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2019 Peter P. Toth, Maciej Banach, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.